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EMCDDA–Europol Joint Report on a new 
psychoactive substance: 1-cyclohexyl-4- 
(1,2-diphenylethyl)piperazine (‘MT-45’)
In accordance with Article 5 of Council Decision 2005/387/JHA 
on the information exchange, risk assessment and control of 
new psychoactive substances
About this series
EMCDDA–Europol Joint Report publications examine the detailed information 
provided by the EU Member States on individual new psychoactive substances. 
Information is collected from the Reitox network, the Europol national units and the 
national competent authorities of the European Medicines Agency.
Each Joint Report serves as the basis upon which the decision to conduct a risk 
assessment of the new psychoactive substance is taken. It is part of the three-step 
procedure involving information exchange, risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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I 1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
referred to as ‘the Council Decision’) stipulates that ‘Where 
Europol and the EMCDDA, or the Council, acting by a majority 
of its members, consider that the information provided by the 
Member State on a new psychoactive substance merits the 
collection of further information, this information shall be 
collated and presented by Europol and the EMCDDA in the 
form of a Joint Report (hereinafter the “Joint Report”).’ The 
Joint Report shall be submitted to the Council of the EU, the 
European Medicines Agency (EMA) and the European 
Commission.
In April 2014 the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) and Europol examined the 
available information on the new psychoactive substance 
1-cyclohexyl-4-(1,2-diphenylethyl)piperazine, commonly 
known as MT-45, through a joint assessment based upon the 
following criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information 
collected on MT-45 satisfied criteria 4, and, in particular, 
criteria 6. The two agencies therefore concluded that sufficient 
information had been accumulated to merit the production of 
a Joint Report on MT-45 as stipulated by Article 5.1 of the 
Council Decision.
I 2. Information collection process
In compliance with the provisions of the Council Decision, on 
16 April 2014 the EMCDDA and Europol launched a procedure 
for the collection of information on MT45, in order to prepare 
the Joint Report. The information was collected mainly 
through the Reitox national focal points in the Member States, 
Turkey and Norway as well as the Europol national units. In 
addition, the EMA collected information through the national 
competent authorities responsible for human and veterinary 
medicinal products in the Member States, Norway, Iceland 
and Liechtenstein. The EMA also provided information as 
relevant to the centralised procedure for authorising medicinal 
products. The information collection process was largely 
(1) OJ L 127, 20.5.2005, p. 32.
concluded by 28 May 2014; additional information and 
clarifications from some countries were received up to four 
weeks after this date.
Europol asked the Europol national units to provide 
information on:
n  the level of MT-45 production in their country;
n  the level of MT-45 distribution in their country;
n  the level of MT-45 trafficking in their country, for internal, 
transit or export purposes;
n  the number of seizures of MT-45 in their country, the total 
amount of the seizures, country of origin, details on the 
physical forms (including photos);
n  the role of organised crime, or criminal groups, in the 
production, distribution and trafficking of MT-45 in their 
country; and,
n  any known aspect of violence and/or money laundering 
relating to the production and trafficking of MT-45.
Europol received responses from 21 Member States (2).
According to Article 5.3 of the Council Decision, the EMA 
requested that the national competent authorities responsible 
for human and veterinary medicinal products in the Member 
States, Norway, Iceland and Liechtenstein provide information 
on whether:
n  the new psychoactive substance MT-45 has obtained a 
marketing authorisation;
n  the new psychoactive substance MT-45 is the subject of an 
application for a marketing authorisation; and,
n  a marketing authorisation that had been granted in respect 
of the new psychoactive substance MT-45 has been 
suspended.
The EMA received responses from 15 Member States and 
Norway (3). The EMA also provided information as relevant to 
the central authorisation procedure.
Furthermore, in anticipation of Article 7.3 of the Council 
Decision in relation to the manufacturing of medicinal 
products in the European Union (EU), the EMA also requested 
information on whether the new psychoactive substance 
MT-45 is used to manufacture a medicinal product:
(2)  Austria, Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, 
Estonia, Finland, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, the 
Netherlands, Poland, Portugal, Romania, Slovenia and Spain.
(3)  Austria, Finland, Germany, Ireland, Sweden and the United Kingdom provided 
a response in relation to human and veterinary medicinal products. Lithuania, 
the Netherlands and Spain provided a response in relation to human 
medicinal products. Belgium, France, Latvia, Poland, Portugal and Slovenia 
provided a response in relation to veterinary medicinal products. Norway 
provided a response in relation to human medicinal products.
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n  which has been granted a marketing authorisation;
n  for which an application has been made for a marketing 
authorisation; and,
n  for which a marketing authorisation has been suspended 
by a competent authority.
The EMA received responses from 15 Member States (4) and 
Norway. The EMA also provided information as relevant to the 
central authorisation procedure.
The EMCDDA collected data through:
1.  a structured questionnaire to the Reitox national focal 
points. The EMCDDA received replies from the 28 Member 
States, Turkey and Norway;
2.  information previously provided to the EU Early Warning 
System, including EMCDDA–Europol Reporting Forms, 
Progress and Final Reports;
3.  a specific information request to the World Health 
Organization on whether or not MT-45 is under assessment 
by the United Nations system (see section 3.5);
4.  a search of open source information which included: 
scientific and medical literature; official reports; grey 
literature; Internet drug discussion forums and related 
websites (hereafter, ‘user websites’); and Internet suppliers 
(which typically appear to be manufacturers and/or 
wholesalers) and retailers selling MT45.
Thus, the information included in sections 3.2.1 and 3.3 of the 
Joint Report was provided by Europol, while the EMCDDA 
provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 
3.6, 3.7, 3.8.1, 3.8.2, 3.8.3 (in part), Annex 1 and Annex 2 (5). 
The information included in sections 3.8.3 (in part), 4.1, 4.2 
and 4.3 was provided by the EMA. The conclusion of the Joint 
Report was prepared and agreed by the EMCDDA and 
Europol, the agencies responsible for the report.
I 3.  Information required by Article 5.2 of the Council Decision
The order and titles of subsections 3.1 to 3.8 and section 4 
below are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; sections are cross-
referenced with those set down in the Council Decision.
(4)  Austria, Finland, Germany, Ireland, Sweden, and the United Kingdom provided 
a response in relation to human and veterinary medicinal products. Lithuania, 
the Netherlands, and Spain provided a response in relation to human 
medicinal products. Belgium, France, Latvia, Poland, Portugal and Slovenia 
provided a response in relation to veterinary medicinal products. Norway 
provided a response in relation to human medicinal products.
(5)  The sections on chemistry, pharmacology and toxicology, dependence liability 
and abuse potential were produced in cooperation with Dr István Ujváry.
I 3.1.  Chemical and physical description, including the names under which the new psychoactive substance is known (Article 5.2(a) of the Council Decision)
Chemical description and names
MT-45 is an N,N-disubstituted piperazine compound, having a 
cyclohexane ring attached to one nitrogen and a 
1,2-diphenylethyl moiety attached to the other nitrogen 
(Figure 1).
MT-45 is an analgesic substance that was developed by the 
Japanese company Dainippon Pharmaceutical Co. Ltd, in the 
early 1970s while searching for analogues of the tricyclic 
tranquilizer-antipsychotic perathiepine and of the structurally 
related analgesic lefetamine (6) (Umemoto et al., 1972; 
Natsuka et al., 1975; Nishimura et al., 1976). The 
pharmacological properties of MT-45 have been extensively 
studied in animals; it appears that it has not been studied in 
humans. Limited mode of action studies were also undertaken 
in vitro. Based on the results of these experiments it appears 
that the pharmacology, including the analgesic activity, of 
MT-45 is complex and involves not only opioid receptors but 
also non-opioid targets that have not been fully characterised 
(section 3.4.1).
The systematic IUPAC name for MT-45 is 1-cyclohexyl-4-(1,2-
diphenylethyl)piperazine.
Other common names or codenames for MT-45 have also 
been reported: I-C6, CDEP and NSC 299236. It has not been 
possible to ascertain the origin of the commonly used name 
MT-45. The name I-C6 comes from the name used during the 
original research published in the scientific literature, with the 
C6 referring to the cyclohexane ring.
No additional chemical synonyms were reported.
One Member State (Belgium) reported that the street name 
‘wow’ has been used in reference to a combination of MT-45 
with methylone (a synthetic cathinone).
(6) Lefetamine is controlled under the 1971 United Nations Convention on 
Psychotropic Substances.
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FIGURE 1
The molecular structure of MT-45. The asterisk (*) denotes a 
chiral centre
*
N
N
Molecular formula: C
24
H
32
N
2
Molecular weight: 348.54
MT-45 is a chiral molecule with one asymmetry centre, thus 
two enantiomers exist. The pure isomers may be obtained by 
resolution of the synthetic racemic mixture. The absolute 
configuration and the optical rotation ([α]22
D
 values) for the 
dihydrochloride salts of (R)-(–) and (S)-(+) isomers are –56.0 
(c 1.0, methanol) and +56.3 (c 2.0, methanol), respectively 
(Natsuka et al., 1975). There is no information on the isomeric 
composition of the samples seized within the EU, which in 
part may reflect the fact that stereochemical analysis is not 
routinely undertaken in forensic laboratories. Of note in this 
respect is that optical rotation was found for MT-45 isolated 
from a collected sample of a liquid drug product purchased in 
Japan in early 2013 indicating that the product contained the 
racemic mixture (Uchiyama et al., 2014).
Chemical Abstract Service (CAS) registry numbers
52694-55-0 racemic free base
57314-55-3 dihydrochloride (2 x HCl) salt
57377-70-5 (R)-isomer
57426-38-7 (R)-isomer dihydrochloride salt
52694-52-7 (S)-isomer
52694-54-9 (S)-isomer dihydrochloride salt
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the 
CAS registry numbers listed above. The searches returned no 
results.
Physical description
The free base of MT-45 is a solid, forming colourless prisms. 
The racemic substance is reported to have a melting point of 
94–95oC. The dihydrochloride salt of the racemic substance 
has a melting point of 270–271oC (melts with decomposition) 
(Natsuka et al., 1975).
A structured search conducted by the EMCDDA of Internet 
suppliers and retailers selling MT-45 (section 3.4.2) found 
that, where specified, the substance is offered as the 
dihydrochloride salt form; in most cases the form offered was 
not specified. Self-reported experiences on user websites 
mention the use of the dihydrochloride salt (Shroomery, 2014; 
Bluelight, 2014).
Information provided from seizures and a collected sample 
reported by the Member States have usually noted the 
presence of MT-45 in powder form. In one instance it was 
detected in a seized sample of brown heroin base. It has also 
been detected in samples of plant material in the presence of 
synthetic cannabinoid substances. In two non-fatal 
intoxications reported by Sweden the physical form used by 
the patients included a tablet in one case and a capsule in the 
other.
A detailed description of MT-45 seizures and a collected 
sample that have been reported can be found in sections 3.2.1 
and 3.2.2.
I
 3.2.  Information on the frequency, circumstances 
and/or quantities in which a new psychoactive 
substance is encountered, and information on 
the means and methods of manufacture of the 
new psychoactive substance (Article 5.2(b) of 
the Council Decision)
3.2.1. Information provided to Europol
Europol received replies from 21 Member States (Austria, 
Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, 
Denmark, Estonia, Finland, Germany, Greece, Hungary, Italy, 
Lithuania, Luxembourg, the Netherlands, Poland, Portugal, 
Romania, Slovenia and Spain). Belgium and Germany reported 
that they had information relating to MT-45.
Belgium provided information about a collected sample of 
powder, which was previously reported to the EMCDDA by the 
Belgian national focal point and is detailed in section 3.2.2.
Germany reported that MT-45 is known to drug users and is 
offered for sale on the Internet. There have been two seizures 
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where MT-45 was detected. The first seizure was in December 
2013 and was 11.3 g of ‘light brown chunky substance’, which 
was identified as heroin base mixed with caffeine, 
paracetamol, sorbitol and MT-45. The second seizure was in 
March 2014, when 250.49 g of white powder was seized which 
was found to contain MT-45 at a concentration of 95 %.
The level of production, distribution and trafficking
No reports were received that indicated licit or illicit 
production of MT-45.
3.2.2. Information provided to the EMCDDA
The EMCDDA received responses from the 28 Member States, 
Turkey and Norway. Of these, two Member States (Belgium 
and Sweden) reported detections of MT-45 (7).
Seizures
Sweden reported 28 seizures of MT-45. In 26 of these, MT-45 
was seized in either white or off-white powder form; the 
quantities seized ranged from 0.1 to 49.9 g. In two of these 
cases another new psychoactive substance was also present 
(α-PBP (8) in one case and 6-APDB (9) in another). In the 
remaining two seizures MT-45 was detected in plant material 
(0.55 g and 0.99 g) in the presence of another new 
psychoactive substance (the synthetic cannabinoid receptor 
agonists AB-FUBINACA (10) and AKB-48 (11) respectively).
Collected samples
Belgium reported a sample of white powder collected from a 
user in March 2014 that contained MT-45 and methylone (12). 
The powder was reportedly sold as ‘a new thing, “wow”’. The 
user apparently experienced strong sedation and was 
concerned that he had ingested something toxic.
Biological samples
Sweden reported 33 detections where MT-45 was analytically 
confirmed in biological samples. These related to: 31 serious 
adverse events, comprised of 10 non-fatal intoxications and 
(7)  ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples that are analytically confirmed. Seizure 
means a substance available (seized) through law enforcement activities 
(police, customs, border guards, etc.). Collected samples are those that are 
actively collected by drug monitoring systems (such as test purchases) for 
monitoring and research purposes. Biological samples are those collected from 
human body fluids (urine, blood, etc.) and/or specimens (tissues, hair, etc.).
(8)  1-Phenyl-2-pyrrolidinobutanone.
(9)  6-(2-Aminopropyl)-2,3-dihydrobenzofuran.
(10)  N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
carboxamide.
(11)  N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide.
(12)  2-Methylamino-1-[3,4-methylenedioxyphenyl]propan-1-one.
21 deaths; and two cases where MT-45 was detected in 
people suspected of committing minor drug offences. The 
non-fatal intoxications and deaths are discussed in section 
3.4.1.
I 3.3.  Information on the involvement of organised crime in the manufacture or trafficking of the new psychoactive substance (Article 5.2(c) of the Council Decision)
No information was provided by Member States in relation to 
the involvement of organised crime in the manufacture or 
trafficking of MT-45.
Money laundering aspects
No information was received on money laundering in 
connection with the production and/or trafficking of MT-45.
Violence in connection with production, wholesale and 
distribution
No information was received on incidents of violence in 
connection with the production, wholesale and/or trafficking 
of MT-45.
I 3.4.  A first indication of the risks associated with the new psychoactive substance, including the health and social risks, and of the characteristics of users — Article 5.2(d) of the Council Decision
3.4.1. First indication of health risks
A total of 34 serious adverse events (13) associated with 
MT-45 were reported by Sweden. These comprised 13 
non-fatal intoxications and 21 deaths.
Non-fatal intoxications
Sweden reported 13 non-fatal intoxications associated with 
MT-45 (Annex 1). These cases were reported by the Swedish 
(13)  Serious adverse event means any adverse event associated with the 
consumption of a new psychoactive substance in a human that: results in 
death; is life-threatening; requires hospitalisation; results in persistent or 
significant disability or incapacity; consists of a congenital anomaly or birth 
defect; or is an important medical event that may not be immediately 
life-threatening or result in death or hospitalisation but may jeopardise the 
patient or may require intervention to prevent one of the other outcomes 
listed above. Examples of such events are intensive treatment in an 
emergency room; convulsions that do not result in hospitalisation; or 
development of substance dependency or substance abuse. Definition 
adapted from ICH Harmonised Tripartite Guideline Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting E2A.
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Poison Information Centre (14) and occurred during 2013 (five 
cases) and 2014 (eight cases). All cases were male and aged 
between 18 and 37. MT-45 was analytically confirmed in 10 of 
the cases.
Ten of the cases were reported to be life-threatening and 
requiring treatment in hospital; two of the cases were not 
life-threatening (15) but required treatment in hospital; while in 
one case this detail was not known. In three of the analytically 
confirmed cases no other substances were detected.
The routes of administration were: oral (five cases); snorted 
(two); intravenous and intramuscular injection and snorted 
(one); oral and rectal (one). In four cases the route of 
administration was not known.
The dose/amount taken was available for three cases: 100 mg 
(oral); 3 g during a week (intravenous and intramuscular 
injection and snorted); and 50 mg (oral).
The reported symptoms were: somnolence (seven cases) or 
unconsciousness (four); tachycardia (seven); decreased 
respiratory rate (three) or apnoea (one); low oxygen saturation 
(two) or hypoxia (one) or cyanosis (one); hypotension (two); 
hearing loss (three); muscular symptoms (two); miosis (two); 
seizures (one); high body temperature (one); hypertension 
(one); hypokalemia (one); and vomiting (one). The opioid 
antagonist naloxone was administered in six of the cases as 
part of their clinical management.
Deaths
Sweden reported 21 deaths associated with MT-45 (Annex 2). 
These cases were reported by the Swedish National Board of 
Forensic Medicine (Department of Forensic Genetics and 
Forensic Toxicology), and occurred in a six-month period 
between November 2013 and April 2014. All cases were male, 
aged between 19 and 43 (mean 29, median 29). In all of these 
cases MT-45 was analytically confirmed and quantified. The 
concentration of MT-45 in post-mortem femoral blood ranged 
from 0.006 to 1.9 μg/g. In 17 of the cases, MT-45 was found in 
combination with at least one other psychoactive substance, 
including controlled substances, new psychoactive 
substances and medicines; in the remaining four cases no 
other substances were detected. In 17 of the cases it was 
reported that the deceased were found dead in a home/
house. The cause of death was reported in 19 cases. In eight 
cases MT-45 was indicated as the cause of death; in eight 
(14)  Details for two of these cases were also provided by the Swedish National 
Board of Forensic Medicine, Department of Forensic Genetics and Forensic 
Toxicology.
(15)  In one of these cases, two different reporting agencies provided information 
on the severity of the intoxication. One agency described it as ‘life-
threatening’ and the other described it as ‘non-life-threatening’. 
cases the cause was reported as mixed intoxication; in two 
cases the cause was reported as pneumonia and intoxication; 
and in one case the cause was reported as injury. The 
investigations into the remaining two cases had not been 
completed at the time of writing the Joint Report.
Serious adverse events from open source information
Two deaths that occurred in August 2013 in the United States 
were identified in a news release by the US Immigration and 
Customs Enforcement’s Homeland Security Investigations. 
These deaths involved a male and a female who were found 
dead in Hamburg, New York State. It was reported that the 
male died of acute intoxication with MT-45 and the female 
died of acute intoxication with MT-45 and ethanol (16).
Pharmacology and mode of action
The synthesis of a series of 1-substituted 4-(1,2-diphenylethyl)
piperazines was described in the early 1970s and was based 
on structural analogies to the antipsychotic perathiepine and 
the analgesic-stimulant lefetamine (also known as (-)SPA). 
Among the first series of compounds prepared, MT-45 stood 
out as a promising analgesic agent as it was almost as potent 
as morphine. The pharmacology and toxicology of MT-45 has 
been extensively studied in animals; it appears that no studies 
have been published that have examined MT-45 in humans. 
Studies involving the racemate as well as the two individual 
stereoisomers revealed a complex mode of action (see below).
The analgesic activity of MT-45 was found to be comparable to 
morphine in several studies (Table 1). The results of a series of 
animal pharmacological studies (Nakamura and Shimizu, 
1976; Fujimura et al., 1978; Imai, 1982; Nozaki et al., 1983) 
have also suggested that the modes of action of MT-45 and its 
individual stereoisomers are partly different from those of 
morphine. The analgesic activity of the (S) isomer is by an 
order of magnitude higher than that of the (R) isomer. In vitro 
studies with rat brain opioid receptor preparations also 
showed that the (S) isomer was a more potent inhibitor of the 
specific binding of naloxone or morphine. The (R) isomer had μ 
opioid receptor (MOP) agonist character although the 
molecular mechanisms appeared to be complex. The (S) 
enantiomer had particularly high affinity for δ and κ opioid 
receptors and interaction at an allosteric site of the receptor 
for the (S) enantiomer was also suggested (Fujimura et al., 
1978; Imai, 1982; Nozaki et al., 1983).
(16)  m.ice.gov/news/releases/1404/140411buffalo.htm?f=m, and personal 
communication to EMCDDA from US Immigration and Customs 
Enforcement’s Homeland Security Investigations. 
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The local anaesthetic activity of the (R) isomer MT-45, as 
determined in the corneal reflex in guinea pigs, was the 
highest compared to the racemic mixture, the (S) isomer and 
procaine with mean effective concentration values of 0.03, 
0.092, 0.16 and 0.27, respectively (Nakamura and Shimizu, 
1976).
At 3 mg/kg and 10 mg/kg subcutaneous doses, MT-45 
dose-dependently reduced gastrointestinal propulsion in the 
mouse but its potency was somewhat weaker than that of 
morphine at the same dosages.
Upon intravenous administration of 1 mg/kg to rabbits, the 
racemic MT-45 and its (S) isomer caused respiratory 
depression by 59 % and 57 %, respectively; the (R) isomer 
failed to cause any respiratory depression even at 5 mg/kg. At 
3 mg/kg, morphine depressed respiration by 63 % in this 
experiment.
A recent study by Matsuno et al. (1998) indicated the 
involvement of sigma receptors in the psycho/neuro/
TABLE 1
Representative analgesic activity data (ED
50
 values in mg/kg) of morphine hydrochloride and MT-45 and its isomers as 
dihydrochloride salts, upon subcutaneous (s.c.) or oral administration (male animals; n=18–54) (Natsuka et al., 1975; Nakamura 
and Shimizu, 1976).
Drug
Mice Rats
Thermal Mechanical Electrical Chemical Thermal Mechanical
Morphine s.c.
oral
2.39
29.4
2.41
15.4
1.22 
7.70
0.58
4.20
3.79
41.0
1.17
32.0
Racemic MT-45 s.c.
oral
3.09
20.9
2.15
11.9
1.54
30.8
2.24
12.5
6.62
29.5
0.73
36.4
(R)-MT-45 s.c.
oral
50.7
no data
27.4
no data
38.3
41.0
36.0
73.3
~75
no data
45.0
no data
(S)-MT-45 s.c.
oral
1.92
20.9
1.09
5.51
0.91
14.8
1.97
10.6
5.39
no data
0.73
26.0
pharmacological activity of (R) isomer of MT-45 showing that 
the substance produced significant memory impairment in the 
mouse passive avoidance performance. Interestingly, this 
memory impairment could be alleviated by subcutaneous 
administrations of sigma receptor agonists. A receptor binding 
study revealed that the substances possessed high affinities 
for both sigma 1 and sigma 2 receptor subtypes (IC
50
 1.4 nM 
and 1.8 nM, respectively).
Acute toxicity in rodents
The acute toxicity of MT-45 was determined in male mice 
and rats, observing mortality for seven days (Nakamura and 
Shimizu, 1976). The LD
50
 values are shown in Table 2. By the 
oral and subcutaneous route, the (S) isomer was more toxic 
than racemic MT-45, though no such difference could be 
observed by the intravenous route. It would also appear that, 
with the exception of subcutaneous injection of the 
racemate, MT-45 preparations are more toxic to rodents than 
morphine.
TABLE 2
Representative acute toxicity data (LD
50
 values in mg/kg) of morphine and MT-45 and its isomers upon oral, subcutaneous (s.c.) 
or intravenous (iv) administration (male animals; n=20–50) (Nakamura and Shimizu, 1976; Nishimura et al., 1976)
Drug
Mice Rats 
oral s.c. i.v. oral s.c. i.v.
Morphine HCl 1402 560 204 335 not tested not tested
Racemic MT-45 2HCl  329 743 §17.8 150 136 7.8
(R)-MT-45 2HCl not tested not tested 17.9 288 97.7 12.9
(S)-MT-45 2HCl 274 320 18.5 not tested not tested 8.0
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It was remarkable that upon subcutaneous administration the 
stereoisomers of MT45 displayed different, dose-dependent 
symptoms indicating different modes of actions: animals 
receiving toxic doses of racemic MT-45 or its (S) isomer died 
with symptoms of severe sedation, muscle rigidity and 
shortness of breath (dyspnoea). Moreover, in lower, non-lethal 
doses the (R) isomer caused sedation while the racemic 
mixture and the (S) isomer caused excitation.
No data are available on the chronic toxicity of MT-45 from 
animal studies.
Dependence potential and abuse liability
The dependence potential of the racemic MT-45 and its (S) 
isomer was assessed in the mouse (Nishimura et al., 1976; 
see also Natsuka et al., 1987). Nalorphine-treatment of mice 
that had received repeated doses of the racemic substance 
precipitated jumping behaviour and other withdrawal signs 
similar to those noted for morphine in the same assay. The 
Straub tail indexes (17) for racemic MT-45, its (S) isomer and 
morphine were estimated to be 7.34, 30 and 33.1, respectively, 
indicating dependence potential for the synthetic piperazine 
derivatives. In addition, MT-45 substituted for morphine in 
morphine-dependent animals.
Some self-reported user experiences (‘trip reports’) on user 
websites suggest withdrawal-like symptoms (Bluelight, 2014).
3.4.2. Characteristics of users
No studies were identified that examined the characteristics 
of users of MT-45. The section below includes a discussion of 
the characteristics of users that includes self-reported use/
experiences from user websites. As such, it is important to 
note that it is not possible to confirm the specific substance(s) 
used, nor the purity, dose/amount, etc. Analysis of new 
psychoactive substances or products containing them that 
are sold on the drug market have shown that the composition 
can differ between that claimed by the retailer and over 
geographical areas and time. In addition, the information 
provided on user websites may not necessarily be 
representative of users of MT-45 in general and should be 
regarded as illustrative only.
(17)  The ‘Straub tail index’ is defined as the ratio of the intravenous LD50 value 
and the Straub tail ED50 value, where the Straub tail ED50 is defined as the 
dose, injected intravenously through the tail vein of the animal, producing 
Straub-reaction in 50 % of the treated animals.
Route of administration, dose, drug regimens and settings 
of use
Information from the non-fatal intoxications reported by 
Sweden and from user websites suggests that the route of 
administration for MT-45 includes oral and nasal (‘snorting’), 
intravenous or intramuscular injection and rectal 
administration. Information from user websites suggests that 
a range of doses may be used: oral doses were between 
25–75 mg with re-dosing reported; doses for nasal insufflation 
were between 15–20 mg (this route of administration was 
noted by several users to cause an intolerable level of 
irritation); one user reported rectal administration of ’80 mg of 
MT-45 salt as the solution’; the same user also reported 
smoking 30–50 mg of MT-45 base, which he prepared from 
the dihydrochloride salt (Bluelight, 2014). Conversely, some 
user reports suggest that higher doses have been used.
Information from the serious adverse events reported by 
Sweden and from user websites suggests that MT-45 may be 
used on its own and in combination with other psychoactive 
substances.
Information from the deaths reported by Sweden and from 
user reports would suggest that MT-45 is used in the home 
environment.
Subjective effects
No studies were identified that have examined the subjective 
effects of MT-45 in humans; information is limited to self-
reported experiences on user websites, which are briefly 
described.
Some users reported feeling high, a ‘decent buzz’ followed by 
sedation; some users added qualifying comments such as 
‘feels good like an opi but lacking euphoria or that good deep 
opi feeling’ or ‘nice calm opiate undertones’. Some typical 
opiate-like effects such as itching were noted by several users 
and nausea appears to be a common feature. Several users 
reported that they experienced analgesia whilst taking MT-45. 
One user reported commencing MT-45 use ‘as I was going into 
heroin withdrawal last week’, suggesting self-medication with 
MT-45 to ease opiate withdrawal symptoms. This was echoed 
by another user, who noted, ‘maybe good to avoid w/d but not 
much recreation in my opinion’. Three users suggested the 
effects were similar to methadone, one compared them to the 
synthetic opioid AH-7921, and one to codeine. No serious 
adverse events were mentioned in these reports (Shroomery, 
2014; Bluelight, 2014; ChemsRus, 2014).
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Availability, supply, price
In three of the non-fatal intoxications reported by Sweden the 
source of the MT-45 was reported to be the Internet. In the 
remaining ten cases the source was unknown.
A structured search by the EMCDDA of Internet suppliers 
(which typically appear to be manufacturers and/or 
wholesalers) and retailers (18) selling MT-45 identified 12 
websites that appear to be based within the EU, Canada, 
China or India (Google, 2014). Five of the websites only 
provided quantities and prices for MT-45 on application. The 
remaining seven websites listed quantities and prices. Briefly: 
the minimum quantity offered was 1 g (n=2 websites) with a 
mean price of EUR 33.25 (EUR 22.16–44.34); the maximum 
quantity offered was 5 000 g (n=1 website) with a price of 
EUR 12,900. Most of the seven websites offered quantities 
ranging from 10 g to 1000 g. The mean price for 10 g (n=5 
websites) was EUR 178.11 (EUR 129–311.01); the mean price 
for 100 g (n=5 websites) was EUR 778.37 (EUR 498.00–
1 107.90); the mean price for 1 000 g (n=5 websites) was 
EUR 3 041.02 (EUR 2 363.52–3 914.58). MT-45 was typically 
sold by these websites as a ‘research chemical’.
Prevalence of use
No prevalence surveys were identified that have examined the 
use of MT-45 either in targeted populations or in the general 
population.
I 3.5.  Information on whether or not the new substance is currently under assessment, or has been under assessment, by the UN system (Article 5.2(e) of the Council Decision)
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the medical, 
scientific and public health aspects of psychoactive 
substances under the 1961 Single Convention on Narcotic 
Drugs and the 1971 Convention on Psychotropic Substances. 
On 14 May 2014 the World Health Organization informed the 
EMCDDA that MT-45 is currently not under assessment and 
has not been under assessment by the UN system and no 
such assessment is planned.
(18)  Using the standardised EMCDDA methodology for monitoring Internet sales 
of new psychoactive substances. Briefly, google.co.uk was searched using 
the term ‘buy “MT-45”’ and the first 100 search results were reviewed. Further 
details on the methodology are available from the EMCDDA on request.
I 3.6.  The date of notification on the Reporting Form of the new psychoactive substance to the EMCDDA or to Europol (Article 5.2(f) of the Council Decision)
The first official notification to the EMCDDA–Europol of MT-45 
dates from December 2013 from the Swedish national focal 
point. The Reporting Form details a seizure of 50 g of white 
powder in October 2013 by the Swedish customs authorities. 
The identification and analytical characterisation was based 
on GC-MS (19), FT-IR (20), LC-MS (21) and NMR (22) at the 
Swedish National Laboratory of Forensic Science.
MT-45 was added to the list of new psychoactive substances 
monitored by the EMCDDA and Europol through the EU Early 
Warning System and a profile of the substance was created on 
the European Database on New Drugs (EDND). Since then, 
analytical details, background information and public health 
alerts have been exchanged between the EMCDDA, Europol 
and the Member States on an ad hoc basis; the European 
Commission and the EMA have been kept duly informed.
I 3.7.  Information on whether or not the new psychoactive substance is already subject to control measures at national level in a Member State (Article 5.2(g) of the Council Decision)
Latvia reported that MT-45 is controlled under drug control 
legislation by being placed under temporary control for 12 
months by the decision of the Centre for Disease Prevention 
and Control (control in force since 15 May 2014) according to 
the Law on Procedures for the Legal Trade of Narcotic and 
Psychotropic Substances and Medicinal Products.
Two Member States (Austria and Poland) reported that MT-45 
is controlled under legislation prohibiting the unauthorised 
supply of defined or qualifying new psychoactive substances. 
In Austria MT-45 is categorised as a member of the ‘(1phenyl 
and 1-benzyl)piperazine’ group in the new psychoactive 
substances law (NPSG law, Group II). In Poland MT-45 falls 
under the definition of a ‘substitution drug’ under the Act 
amending the Act on Counteracting Drug Addiction and the 
Act on State Sanitary Inspection, 2010, and as such its 
marketing and production is penalised with a fine 
(administrative sanctions).
In the Netherlands the sale of MT-45 in consumer amounts is 
treated as a medicinal product and must comply with 
medicines legislation.
(19)  Gas chromatography-mass spectrometry.
(20)  Fourier transform-infrared spectroscopy.
(21) Liquid chromatography-mass spectrometry.
(22)  Nuclear magnetic resonance spectroscopy.
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Spain reported that ‘although there is no current specific 
legislation controlling production, commerce, imports, exports 
or use/consumption of this substance and given that it may 
cause harmful effects to those using it — the same way as 
illegal drugs do — there is generic legislation (administrative 
and criminal) on health protection which is fully applicable, if 
necessary.’
Twenty-three Member States (Belgium (23), Bulgaria, Croatia, 
Cyprus, the Czech Republic, Denmark, Estonia, Finland, 
France, Germany, Greece, Hungary, Ireland, Italy, Lithuania, 
Luxembourg, Malta, Portugal, Romania, Slovakia, Slovenia, 
Sweden and the United Kingdom), Turkey and Norway 
reported that MT-45 is not subject to control measures at the 
national level.
I 3.8.  Further information (Article 5.2(h) of the Council Decision)
3.8.1.  The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported about the chemical precursors or 
manufacturing methods used to make the MT-45 that has 
been detected within the EU.
Two synthetic methods for the manufacture of MT-45 and 
closely related analogues have been described in the patent 
and scientific literature (Natsuka et al., 1975; Nishimura et al., 
1976). In one of the routes the key precursor is the 
commercially available 1,2-diphenylethylamine, which upon 
alkylation with N,N-bis(2-chloroethyl)cyclohexanamine can be 
converted in one step to MT-45. Alternatively, MT-45 can be 
prepared by the alkylation of cyclohexylamine with N,N-bis(2-
chloroethyl)-1,2-diphenylethanamine, which can be obtained 
by a multi-step process involving a Grignard reaction. Other 
synthetic methods are feasible. Note that these routes afford a 
1:1 mixture of the (S) and (R) enantiomers each possessing 
distinct biological activities (section 3.4.1). The separation of 
the enantiomers from this racemic mixture requires optical 
resolution that has been accomplished.
3.8.2.  The mode and scope of the established or 
expected use of the new substance
No studies were identified that have examined the mode and 
scope of established or expected use of MT-45. Given the 
(23)  Belgium reported that MT-45 is included in the new generic drug legislation 
that will come into effect later in 2014 after the Royal Decree has been 
signed. 
limited information currently available, the relevant 
information has been included in the previous sections.
3.8.3.  Other use of the new psychoactive substance 
and the extent of such use, the risks associated 
with this use of the new psychoactive substance, 
including the health and social risks
No information was provided by any Member State that 
indicated that MT-45 had any other use apart from in 
legitimate scientific research and in analytical reference 
materials.
From the available information, it does not appear that MT-45 
is used in the manufacture of a medicinal product in the EU; 
however, the data collection is incomplete and some countries 
indicated that this information is not known. Six Member 
States (Finland, Lithuania, the Netherlands, Spain, Sweden 
and the United Kingdom) provided information that MT-45 is 
not used to manufacture a medicinal product for human use. 
Three Member States (Austria, Germany and Ireland) and 
Norway replied that they did not know this information. Seven 
Member States (Belgium, Finland, France, Latvia, Poland, 
Sweden and the United Kingdom) provided information that 
MT-45 is not used to manufacture a medicinal product for 
veterinary use. Five Member States (Austria, Germany, Ireland, 
Portugal and Sweden) replied that they did not know this 
information (24).
In addition, the EMA reported that it is not known if MT-45 is 
used in the manufacture of medicinal products for human or 
veterinary use in the EU. It is understood that the collection of 
such information is a challenge in the absence of a EU 
database on the synthetic routes of all medicinal products.
I 4.  Information from the EMA (Article 5.3 of the Council Decision)
I 4.1. Marketing authorisation
Fifteen Member States and Norway responded to the EMA’s 
information request (section 2). They reported that the new 
psychoactive substance MT-45 has not obtained a marketing 
(24)  Austria, Finland, Germany, Ireland, Sweden and the United Kingdom provided 
a response in relation to human and veterinary medicinal products. Lithuania, 
the Netherlands and Spain provided a response in relation to human 
medicinal products. Belgium, France, Latvia, Poland, Portugal and Slovenia 
provided a response in relation to veterinary medicinal products. Norway 
provided a response in relation to human medicinal products. 
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authorisation (25). The EMA also reported that the new 
psychoactive substance MT-45 has not obtained a marketing 
authorisation through the centralised procedure for 
authorising medicinal products.
I 4.2. Application for a marketing authorisation
Fifteen Member States and Norway responded to the EMA’s 
information request (section 2). They reported that the new 
psychoactive substance MT-45 is not the subject of an 
application for a marketing authorisation (24). The EMA also 
reported that the new psychoactive substance MT-45 is not 
the subject of an application for a marketing authorisation 
through the centralised procedure.
I 4.3. Suspended marketing authorisation
Fifteen Member States and Norway responded to the EMA’s 
information request (section 2). They reported that there had 
been no cases of a suspended marketing authorisation that 
had been granted in respect of the new psychoactive 
substance MT-45 (24). The EMA also reported that the new 
psychoactive substance MT-45 is not the subject of a 
suspended marketing authorisation through the central 
authorisation procedure.
(25)  I.e. products that have been granted a marketing authorisation, or where an 
application for a marketing authorisation has been made, or where the 
marketing authorisation has been suspended. 
I 5. Conclusion
MT-45 is a synthetic opioid. It has been available in the EU 
since at least October 2013 and has been detected in three 
Member States: Belgium, Germany and Sweden. In most 
cases it has been seized in small quantities as a powder. Over 
a short period of time MT-45 has been associated with 13 
non-fatal intoxications and 21 deaths in Sweden. It is sold as a 
‘research chemical’ online and offered in wholesale and 
consumer amounts. MT-45 is similar to morphine in some 
aspects of its pharmacology, although in some animal studies 
it exhibited a higher toxicity than morphine. There has been 
one case where MT-45 was detected in a seized sample of 
brown heroin base.
We conclude that the health and social risks caused by the 
manufacture, trafficking and use of MT-45, and the 
involvement of organised crime and possible consequences of 
control measures, could be thoroughly assessed through a 
risk assessment procedure in accordance with Article 6 of 
Council Decision 2005/387/JHA.
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I  Annex 1 Non-fatal intoxications reported by Sweden where MT-45 was analytically confirmed in biological samples
Case
Toxicology results
(biological matrix:  
blood and urine)
Route of administration 
(physical form) and  
amount of MT-45 taken
Contextual information
(self-reported intake of  
other substances,  
source for MT-45)
Details of the serious adverse event:
– clinical symptoms, treatment
– why the event was considered serious
1 MT-45 (+) Oral; 100 mg – –  Hypertension, tachycardia, muscular 
symptoms.
–  Non life-threatening event, but required 
treatment in hospital.
2 MT-45 (+) 
Dextromethorphan (+) 
Methiopropamine (+) 
THC (+)
– – –  Constricted pupils, unconsciousness, 
cyanosis, tachycardia. Naloxone was 
administered.
–  Life-threatening event requiring 
treatment in hospital.
3 MT-45 (+) 
Flubromazepam (+) 
Pyrazolam (+) 
THC (+)
Injected (intravenous and 
intramuscular) and snorted; 
3 g during a week
α-PBP (1 g) 
MT-45 obtained from the 
Internet
–  Somnolence, hypotension, tachycardia, 
low oxygen saturation. Naloxone was 
administered.
–  Life-threatening event requiring 
treatment in hospital.
4 MT-45 (+) 
3-MeO-PCP
Snorted ‘Maybe some stimulating 
drugs’ 
MT-45 obtained from the 
Internet
–  Somnolence, apnoea, hearing loss. 
Naloxone was administered.
–  Life-threatening event requiring 
treatment in hospital.
5 MT-45 (+) 
Oxycodone (+) 
Pregabalin (+)
Oral; 50 mg Flubromazepam 
MT-45 obtained from the 
Internet
–  Somnolence, hypotension, tachycardia.
–  Life-threatening event requiring 
treatment in hospital.
6 MT-45 (330 µg/g, blood) 
THC (+)
– – –  Somnolence, decreased respiratory rate, 
tachycardia, hearing loss, muscular 
symptoms. Naloxone was given.
–  Life-threatening event requiring 
treatment in hospital.
7 MT-45 (0.06 µg/g blood) 
Flubromazepam (+)
– – –  Somnolence, tachycardia.
–  Described as both life-threatening and 
non-life-threatening event by two 
different reporting agencies; required 
treatment in hospital.
8 MT-45 (+) Oral, rectal – –  Somnolence, decreased respiratory rate, 
tachycardia.
–  Life-threatening event requiring 
treatment in hospital.
–  Outcome not known.
9 MT-45 (+) – – –  Unconsciousness, hypoxia, vomiting, 
hearing loss.
–  Life-threatening event requiring 
treatment in hospital.
10 MT-45 (+) 
3-MMC/4-MMC (+) 
Flubromazepam (+) 
Pyrazolam (+)
Oral (powder) – –  Unconsciousness, decreased 
respiratory rate, hypokalaemia. Naloxone 
was given.
–  Life-threatening event requiring 
treatment in hospital.
Note: Intoxications occurred during 2013 (four cases) and 2014 (six cases). All cases were males, aged between 18 and 37.
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I  Annex 2 Deaths reported by Sweden where MT-45 was analytically confirmed in biological samples (quantified in femoral blood using LC/MS/MS) and for which cause of death is stated
Case
Toxicology results 
for MT-45
Toxicology results for other substances Circumstances Cause of death
1 1.9 µg/g No other substances detected Found dead at home MT-45 intoxication
2 0.82 µg/g 0.51 µg/g  quetiapine Found dead at home MT-45 intoxication
3 0.46 µg/g 27 µg/g gabapentin 
1.3 µg/g  methiopropamine 
0.43 µg/g  flubromazepam 
+  pyrazolam 
+  ethylphenidate
Found dead at home Mixed intoxication
4 0.008 µg/g 0.06 µg/g  alprazolam 
5.5 µg/g  gabapentin 
0.02 µg/g  morphine 
0.6 ng/g  THC
Not known Pneumonia + intoxication
5 0.38 µg/g 0.16 µg/g  flubromazepam 
0.1 µg/g  sertraline 
0.3 µg/g desmethylsertraline
+  pyrazolam
Found dead at home Pneumonia + intoxication
6 0.35 µg/g 0.03 µg/g  mirtazapine 
0.02 µg/g desmethylmirtazapine 
0.6 µg/g  APDB (26)
Found dead at home Mixed intoxication
7 0.93 µg/g 0.57 µg/g  fluoxetine 
0.51 µg/g  norfluoxetine
Found dead at home MT-45 intoxication
8 1.0 µg/g 0.02 µg/g  oxycodone 
0.12 µg/g  flubromazepam 
Found outside, cardiac arrest, 
died in hospital
MT-45 intoxication
9 0.51 µg/g 0.1 µg/g  flubromzepam 
0.3 µg/g  sertraline 
0.6 µg/g desmethylsertraline 
0.79 µg/g  tramadol
Found dead at home Mixed intoxication
10 0.39 µg/g 2.3 µg/g  gabapentin 
1.0 µg/g  lamotrigine 
0.08 µg/g  amphetamine 
+  ethanol
Found unconscious, died in 
hospital
Mixed intoxication
11 0.27 µg/g 4 µg/g  gabapentin 
0.03 µg/g  codeine 
+  methiopropamine 
+  2-aminoindane
Found dead at home MT-45 intoxication
12 0.16 µg/g 0.09 µg/g  flubromazepam 
+  diclazepam
Died at a friend’s house Mixed intoxication
13 0.19 µg/g 0.6 µg/g  alimemazine 
5.3 ng/g fentanyl 
0.3 µg/g  fluoxetine 
0.24 µg/g  norfluoxetine 
0.05 µg/g  bupropion 
0.01 µg/g  alprazolam 
0.04 µg/g  nordiazepam
Found dead at home Mixed intoxication (opioids)
14 0.09 µg/g 0.61 µg/g  codeine 
0.06 µg/g  morphine 
0.03 µg/g  hydrocodone 
0.03 µg/g  diazepam 
0.10 µg/g  nordiazepam 
0.08 µg/g  olanzapine 
0.05 µg/g desmethylolanzapine 
+  ethanol
Found dead at home Mixed intoxication (ethanol and 
drugs)
15 0.2 µg/g No other substances detected Found dead at home MT-45 intoxication
(26) 4,5 or 6-(2-aminopropyl)-2,3-dihydrobenzofuran
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Annex 2
Case
Toxicology results 
for MT-45
Toxicology results for other substances Circumstances Cause of death
16 0.35 µg/g 0.5 µg/g alimemazine 
0.5 µg/g desmethylalimemazine
+  diclazepam
Found dead at home Mixed intoxication (alimemazine, 
MT-45 and diclazepam)
17 0.15 µg/g No other substances detected Jumped off a building Injury
18 0.77 µg /g No other substances detected Found dead at home MT-45 intoxication
19 0.46 µg/g 5.9 µg/g  gabapentin
0.12 µg/g  diazepam
0.008 µg/g  alprazolam
1.1 µg/g  venlafaxine
0.4 µg/g desthylvenlafaxine
3.02 µg/g  carbamazepine
0.06 µg/g  alimemazine
0.07 µg/g levomepromazine
Found dead at home MT-45 intoxication
Note: Deaths occurred between November 2013 and April 2014. All cases were male, aged between 19 and 43.
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